Uptravi bulk
Ended Awarded Last action
- Contract number
- 36C26025F0004
- Awardee
-
Actelion Pharmaceuticals US, Inc. UEI H5BMHLMMNA28
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $334,527
Award facts
- Contract value 100% obligated
- $334,526.73 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Normandy, MO 63121, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$78,222 | |
| Original award | $412,749 |
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 20, awarded a delivery order to Actelion Pharmaceuticals US, Inc. on October 1, 2024, for UPTRAVI Bulk pharmaceutical supplies. This firm fixed-price delivery order is valued at $334,526.73 with an ultimate completion date of September 30, 2025, and will be performed in Normandy, Missouri. Actelion is a pharmaceutical manufacturer specializing in rare disease treatments, particularly pulmonary arterial hypertension medications. UPTRAVI (selexipag) is one of Actelion's core products in this therapeutic area and is procured to support veterans' healthcare needs across the VA system. No small business set-aside designation was utilized for this award.
This delivery order is issued under Actelion's Federal Supply Schedule contract (FSS-61-IB) for Pharmaceuticals and Drugs, valued at $219.1 million and effective through July 31, 2029, which enables streamlined procurement of specialized pharmaceutical products across federal healthcare institutions. Actelion also maintains a single-award Blanket Purchase Agreement valued at $118.5 million that includes UPTRAVI among its core product portfolio. As the prime contractor, Actelion supplies these specialized medications directly to federal agencies with no identified subcontractor involvement. The company's federal contract portfolio reflects its critical role as a supplier of advanced therapeutic medications for complex medical conditions affecting veterans, federal prisoners, and other eligible federal beneficiaries nationwide.
Quick answers
Who was awarded contract 36C26025F0004?
36C26025F0004 was awarded to Actelion Pharmaceuticals US, Inc. by Veterans Integrated Service Network 20 (Veterans Health Administration) on October 1, 2024.
How much is contract 36C26025F0004 worth?
The government has obligated $334,527 on 36C26025F0004.
Is contract 36C26025F0004 an order under another contract?
Yes. 36C26025F0004 is a delivery order under 36F79719D0142, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26025F0004 competed?
The extent of competition for 36C26025F0004 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award